The Kidney-Inflammation Axis: Why MSCs Entered the Conversation

Chronic kidney disease kills more people worldwide than breast or prostate cancer — yet treatment options beyond ACE inhibitors, SGLT2 inhibitors, and eventual dialysis remain limited. The underlying driver? Persistent, low-grade inflammation that gradually scars the nephron architecture beyond repair.

Mesenchymal stem cells (MSCs) have attracted nephrology researchers precisely because of their anti-inflammatory profile. Unlike many cell therapies that engraft and differentiate, MSCs work primarily through paracrine signaling — secreting cytokines, growth factors, and extracellular vesicles that modulate the immune microenvironment. The question isn’t whether MSCs can reduce inflammation in a petri dish. It’s whether that mechanism translates to preserved glomerular filtration rate (GFR) in actual patients with CKD.

2025 Meta-Analysis: What 52 Studies Tell Us About MSCs and CKD Inflammation

The most comprehensive synthesis to date came from Pura et al. at Universitas Padjadjaran in Indonesia, published in Cells in August 2025. Their systematic review screened 2,514 studies and included 52 — 49 animal models and 3 randomized controlled trials (RCTs) in humans.

In the animal data, the results were striking:

• IL-6 reduction: Mean difference of -155.80 (95% CI: -249.10 to -62.51; p = 0.001)
• TNF-α reduction: Mean difference of -35.53 (95% CI: -52.75 to -18.30; p < 0.0001)
• Serum creatinine: Decreased by -0.38 mg/dL (95% CI: -0.46 to -0.29; p < 0.00001)
• Blood urea nitrogen: Dropped by -19.27 mg/dL (95% CI: -23.50 to -15.04; p < 0.00001)
• GFR improvement: Standardized mean difference of 1.83 (95% CI: 0.51 to 3.15; p = 0.007)

But here’s the important caveat for clinicians: in the three human RCTs pooled, TNF-α reduction didn’t reach statistical significance (MD = -0.74; p = 0.32), and serum creatinine changes were similarly non-significant (MD = -0.59; p = 0.39). The gap between animal models and human trials remains the central challenge in this field.

Real-World Evidence from Taiwan: Allogeneic ADSCs for Advanced CKD

Lin et al. took a different approach. Instead of pooling RCTs, they used real-world clinical data as an external control — a methodology gaining traction in regenerative medicine trials where placebo randomization raises ethical concerns.

Published in Clinical and Translational Science (December 2025), the study matched 34 patients who received allogeneic adipose-derived stem cell (ADSC) therapy with 170 control patients from clinical databases (1:5 ratio). Key findings:

• The treated group showed a more stable renal function trajectory compared to controls
• Patients with more advanced disease benefited most — a counterintuitive but clinically relevant finding
• The low-dose group paradoxically showed the greatest stability in eGFR, suggesting dose-response isn’t linear
• Registered on ClinicalTrials.gov as NCT02933827, providing a transparent trial framework

That low-dose finding deserves attention. Several MSC trials across indications have noted that higher doses don’t always produce better outcomes — the immunomodulatory effect may saturate, or excessive cell burden could trigger clearance mechanisms. For nephrologists designing protocols, this suggests starting conservatively.

The Mayo Clinic Approach: Intraarterial Delivery for Diabetic Kidney Disease

Alatta et al. at Mayo Clinic published a case series in Kidney International Reports (October 2025) examining intraarterial autologous MSC delivery specifically for diabetic kidney disease (DKD). This delivery route is notable — most MSC trials use intravenous infusion, but IV-delivered cells get trapped in the lungs first-pass (the “pulmonary first-pass effect”). Intraarterial catheterization of the renal artery targets the kidney directly.

The Mayo team leveraged their interventional radiology infrastructure to deliver cells precisely to the renal vasculature. While this paper is a smaller case series rather than a large RCT, the direct-delivery concept represents a meaningful engineering advancement in how MSCs reach the target organ. For DKD patients — who represent the single largest CKD subpopulation globally — targeted delivery could theoretically reduce the cell dose needed while increasing local concentration.

Unexpected Finding: MSCs and the Aging Kidney

One of the most intriguing 2025 findings came from an unexpected source. Martinez-Lemus et al. at UTHealth Houston published secondary results from a Parkinson’s disease RCT in Stem Cell Research & Therapy (September 2025), examining what repeated allogeneic bone marrow-derived MSC infusions did to kidney function in aging adults.

The trial (NCT04506073) randomized 45 participants aged 50–79 with PD and preserved kidney function (eGFR >60 mL/min/1.73 m²) into three arms:

• Three MSC infusions (N=16): Average annual eGFR increase of +3.29 mL/min/1.73 m²
• One placebo + two MSC infusions (N=14): eGFR decline of -1.46 mL/min/1.73 m²/year
• Three placebos (N=15): eGFR decline of -2.92 mL/min/1.73 m²/year

Serum creatinine decreased by -0.12 mg/dL at both week 40 (posterior probability: 93.9%) and week 88 (PP: 86.2%) in the three-infusion group versus placebo. These are aging adults without CKD — but the natural decline in kidney function with age is well-documented, and the signal here suggests MSCs may slow that trajectory.

The Bayesian modeling approach used here is worth noting. Traditional frequentist analysis often misses signals in small trials; Bayesian posterior probabilities give a different lens — and the 93.9% PP at week 40 is a strong signal even if it doesn’t clear the conventional p < 0.05 threshold in a frequentist framework.

Immunomodulation: The Mechanism Layer

Li et al. at Xijing Hospital published a literature review in BMC Nephrology (March 2025) that synthesizes the immunomodulatory mechanisms at play. Their key mechanistic points:

• Regulatory T cell (Treg) expansion: MSCs shift the immune balance from pro-inflammatory Th1/Th17 toward anti-inflammatory Treg populations
• Paracrine signaling: The therapeutic effect comes largely from the MSC secretome — exosomes, cytokines, and growth factors — rather than direct cell engraftment
• Anti-fibrotic activity: MSC-derived factors inhibit myofibroblast activation and collagen deposition in renal interstitium
• Angiogenesis promotion: MSCs support peritubular capillary repair, which is critical since microvascular rarefaction drives CKD progression

The review also highlights what most clinicians want to know: MSC infusion can improve GFR, reduce urine protein, lower serum creatinine, and decrease BUN — but the degree of improvement varies by cell source (umbilical cord vs. bone marrow vs. adipose), injection route, and dosing schedule. There’s no standardized protocol yet.

Active Clinical Trials: What’s Recruiting Now

Several trials on ClinicalTrials.gov are actively recruiting CKD patients for MSC therapy:

• NCT05018845: Safety of allogeneic umbilical cord-derived MSC IV infusion for CKD (Phase 1)
• NCT03478215: MSCs in living donor kidney transplantation (Phase 2, active not recruiting)
• NCT07572890: Adia Med CKD research study (Phase 1, recruiting)
• NCT02808208: Autologous ADSCs in reducing hemodialysis AV fistula failure (Phase 1, active not recruiting)

The transplant trials are particularly interesting — if MSCs can reduce the immunosuppressive burden post-transplant while preserving graft function, that’s a meaningful quality-of-life improvement for transplant recipients.

Clinical Translation: Where the Evidence Stands

Let’s be direct about what the 2025 literature tells practicing nephrologists:

1. MSCs demonstrably reduce inflammatory markers in CKD animal models. The preclinical signal is consistent across dozens of studies. This isn’t in dispute.
2. Human evidence is early-stage but directionally positive. Three RCTs, real-world matched cohorts, and secondary analyses all point toward renal function stabilization — but no trial has yet powered for hard endpoints like time to dialysis or mortality.
3. Dosing matters more than expected. The Taiwan study’s low-dose superiority and the Houston study’s three-infusion requirement both suggest that less frequent, lower-dose protocols may outperform aggressive dosing.
4. Delivery route is an active optimization target. IV infusion remains standard, but intraarterial (Mayo Clinic) and intrathecal routes are being tested for organ-specific delivery.
5. Cell source influences outcomes. Umbilical cord MSCs, bone marrow MSCs, and adipose-derived MSCs have different secretome profiles. Head-to-head comparisons in CKD are lacking.

Frequently Asked Questions

Is MSC therapy approved for CKD treatment?

No regulatory agency (FDA, EMA, or Thai FDA) has approved MSC therapy specifically for CKD. Current use falls under experimental or compassionate-use frameworks. Clinical trials are the appropriate avenue for patients interested in this approach.

How do MSCs help the kidneys if they don’t replace damaged cells?

MSCs work through paracrine signaling — they release anti-inflammatory cytokines, growth factors, and extracellular vesicles that modulate the local immune environment. In CKD, this means reducing the chronic inflammation that drives fibrosis and nephron loss. They’re not rebuilding glomeruli; they’re changing the biochemical environment to slow further damage.

What’s the difference between autologous and allogeneic MSC therapy for CKD?

Autologous means your own cells are harvested, expanded, and reinfused. Allogeneic uses donor cells — often from umbilical cord or bone marrow banks. The Taiwan real-world study used allogeneic adipose-derived cells, while the Mayo Clinic series used autologous cells. Allogeneic is more “off-the-shelf” and doesn’t require harvesting, but autologous eliminates graft-versus-host risk. The evidence doesn’t clearly favor one over the other in CKD yet.

Are there risks specific to MSC therapy in kidney patients?

The primary concern in CKD patients is cell clearance — damaged kidneys may process infused cells differently. Intraarterial delivery carries procedural risks (arterial access, contrast nephropathy). Immunogenicity with repeated allogeneic dosing is also being studied. Overall, MSC trials in CKD have reported favorable safety profiles, but long-term data beyond 2 years is limited.

What should I discuss with my nephrologist before considering MSC therapy?

Ask about: (1) your current eGFR trajectory — rapidly declining patients may benefit most; (2) whether you qualify for any active clinical trials (check ClinicalTrials.gov); (3) the source and quality standards of any proposed cells; and (4) realistic expectations — stabilization rather than reversal is the current evidence-based goal.

Book Your Free Consultation →

использованная литература

1. Pura L, Putri RD, Prahmana MA, et al. Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cells. 2025;14(17):1313. doi: 10.3390/cells14171313
2. Lin YC, Hung YP, Tian YC, et al. Real-World Data as External Control in Assessing the Efficacy of Allogeneic Adipose-Derived Stem Cells Therapy for Advanced Chronic Kidney Disease. Clin Transl Sci. 2025;18(12):e70415. doi: 10.1111/cts.70415
3. Martinez-Lemus JD, Molony DA, Suescun J, et al. Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial. Stem Cell Res Ther. 2025;16(1):493. doi: 10.1186/s13287-025-04577-y
4. Li J, Wu M, He L. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrol. 2025;26(1):107. doi: 10.1186/s12882-025-04029-y
5. Alatta LS, Elhusseiny KM, Dietz AB, et al. Intraarterial Autologous Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease. Kidney Int Rep. 2025;10(10):3656-3660. doi: 10.1016/j.ekir.2025.07.042